Preliminary Conference Program

Similar documents
Preliminary Conference Program

for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 6-8 March 2019 Barcelona Spain

Letter from the Chairman (Dermot O Toole)

ENETS Consensus Guidelines for the Standard of Care in

10 th Annual ENETS Conference


ENETS Aims & Key Dates... 5 Welcome Letter from the ENETS Chairman... 7 EACCME - UEMS Accreditation Statement

Letter from the Chairman

ENETS Aims & Key Dates... 5 Welcome Letter from the ENETS Chairman... 7 EACCME - UEMS Accreditation Statement

Letter from the Chairman

2015: Year in Review Results of Recent Trials

Neuroendocrine Tumours

A Newsletter for Medical Professionals and ENETS Members

Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives

TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS

Recent developments of oncology in neuroendocrine tumors (NETs)

Review of Gastrointestinal Carcinoid Tumors: Latest Therapies

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

NET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ

MEDICAL MANAGEMENT OF METASTATIC GEP-NET

A Newsletter for Medical Professionals and ENETS Members

ESSO Course on Diagnosis and Treatment of Pancreatic NeuroEndocrine Tumours (PNETs)

Cutting Edge Treatment of Neuroendocrine Tumors

Cutting Edge Treatment of Neuroendocrine Tumors

A Newsletter for Medical Professionals and ENETS Members

Ongoing and future clinical investigation in GEP NENs

WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer

Nuevas alternativas en el manejo de TNE avanzados

Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal

A Newsletter for Medical Professionals and ENETS Members

The PET-NET Study 2016 CNETS Grant Award

Treatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece

Selection of Appropriate Treatment

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

ISRAELI NEUROENDOCRINE TUMORS PROGRAM

OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS

Peptide Receptor Radionuclide Therapy using 177 Lu octreotate

Background. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):

Evaluation and Management of Neuroendocrine Tumors

Case Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT

Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC

Pancreatic Neuroendocrine Tumours

GEP NET: algoritmo terapeutico. Dottor Nicola Fazio

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Lu 177-Dotatate (Lutathera) Therapy Information

GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust

Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.

ENETS Consensus Guidelines. Neuroendocrinology 2016;103: DOI: /

NET und NEC. Endoscopic and oncologic therapy

14th International Workshop Multiple Endocrine Neoplasia and other rare endocrine tumors. September 25 27, Vienna - Austria.

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

EXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others

NICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued

ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany

Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique

Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland

PANCREATIC NEUROENDOCRINE TUMOURS A

EASL HCC SUMMIT 2018 FROM BASIC TO CLINICAL RESEARCH: HOW TO IMPROVE HCC CLINICAL CARE? 01 03, MARCH 2018 GENEVA, SWITZERLAND

ISRAELI NEUROENDOCRINE TUMORS PROGRAM

Schweizer Register für Neuroendokrine Tumore Le Registre Suisse des tumeurs neuroendocrines Registro Svizzero per i Tumori Neuroendocrini

Net Cancer Day Webinar

Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours

SUPPLEMENTARY INFORMATION

THERANOSTICS MOLEKULARE BILDGEBUNG MITTELS PET/CT

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

Octreotide LAR in neuroendocrine tumours a summary of the experience

Specialised Services Policy CP66: 68-gallium DOTA- peptide scanning for the Management of Neuroendocrine Tumours (NETs)

NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες

LIVER TRANSPLANTATION IN A YOUNG PATIENT WITH SEVERE AND REFRACTORY CARCINOID SYNDROME

*Bert Bakker was an employee of Novartis Pharmaceuticals Corporation until June 06, 2014.

HCC and the Hallmarks of Cancer: steps towards novel therapeutic strategies

FOCUS ON NEUROENDOCRINE TUMORS 7 TH ANNUAL. Friday, April 13, am 2 pm. REGISTER ONLINE AT PennMedicine.org/Abramson/NETs

Review Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature

Sunitinib Achieved Fast and Sustained Control of VIPoma. Symptoms

Therapeutic Radiopharmaceuticals in Oncology

Crown Plaza Hotel, the Dead Sea PROGRAM

A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands

Neuroendocrine Tumour Theranostics

Recent Advances in Gastrointestinal Cancers

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

Future outlooks in NET: The pathologists point of view. Aurel Perren, Institute of Pathology University of Bern

A New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy

Consensus guidelines for high grade gastro entero pancreatic (GEP) neuroendocrine tumours and neuroendocrine carcinomas (NEC)

Management of Neuroendocrine Tumors

Rodney J Hicks, MD, FRACP, FAAHMS, the Peter MaCallum Cancer Centre, Melbourne, Australia

17th. Endocrine Surgery. International Postgraduate Course in. Scientific Programme 31/5-2/6

Neuroendocrinology (DOI: / ) (Accepted, unedited article not yet assigned to an issue) Advanced Release: April 13, 2017

Antiangiogenics are effective treatments in NETs

Gastrointestinal Oncology

Addison's disease Neuroendocrine tumors Paraneoplastic syndromes

FOCUS ON NEUROENDOCRINE TUMORS 8 TH ANNUAL. Friday, March 8, am 2:30 pm. REGISTER ONLINE AT PennMedicine.org/Abramson/NETs

5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology

GEP NEN. Personalised approach. Curative and Palliative Surgery. ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano April 2018

NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

Consensus guidelines update for colorectal neuroendocrine

Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy

MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

Transcription:

Preliminary Conference Program

Table of Contents ENETS Scientific Conference Program... 4 09.03.2016... 4 ENETS Postgraduate Course... 4 Welcome Reception... 5 10.03.2016... 6 Meet the Professor... 6 Welcome and Introduction... 6 Session 1: New Understanding in NET Tumorigenesis... 6 Life Achievement Award 2016... 6 Presentation ENETS Grant Winners 2015... 7 Coffee Break and Poster Viewing... 7 Session 2A: Predictive Biomarkers for NETS... 7 Session 2B: Pancreas Session with Treatment... 7 Satellite Symposium I, Industry - Sponsored - Symposium... 7 Lunch... 8 Session 3A: Basic Science Abstract Session... 8 Session 3B: Clinical Abstract Session... 8 Coffee Break and Poster Viewing... 8 Session 4: ENETS / EANM Joint Symposium: PRRT - Peptide Receptor Radionuclide Therapy... 8 ENETS General Assembly... 9 Satellite Symposium II, Industry - Sponsored - Symposium... 9 Meet the Professor... 9 11.03.2016... 10 Session 5: Surgical Debate - Transplant Versus Liver Resection... 10 Coffee Break and Poster Viewing... 10 Session 6A: Treatment of NET G3 OR NEC... 10 Session 6B: Neuroendocrine Tumor Models... 10 Session 7Ai: Molecular Targeted Agents and Angiogenesis... 11 Session 7B: ENETS NET Nurse Symposium... 11 Session 7Aii: ENETS Surgical Trials... 11 ENETS Awards and Grants Ceremony 2016... 12 Satellite Symposium III, Industry - Sponsored - Symposium... 12 Lunch... 12 Session 8: What s New in the Field?... 12

Table of Contents Closing Comment... 13 Contact info... 14

Scientific Program 4 Wednesday, 09.03.2016 ENETS Postgraduate Course Time: Wednesday 08:15-17:15 Room: Meeting room 112 Chairs: Dermot O'Toole, IRL; Martyn Caplin, GBR; Massimo Falconi, ITA; Rocio Garcia-Carbonero, ESP Chairs for the Session from 9:15 11:00 will be Martyn Caplin, GBR / Rocio Garcia-Carbonero, ESP Chairs for the Sessions from 11:30 12:40 will be Massimo Falconi, ITA / Rocio Garcia-Carbonero, ESP Chairs for the Sessions from 13:40 14:50 will be Dermot O Toole, IRL / Rocio Garcia-Carbonero, ESP Chairs for the Sessions from 15:10 17:00 will be Martyn Caplin, GBR / Marianne Pavel, GER The postgraduate program is designed for clinicians and researchers new to NET diagnosis and therapy. Limited seats, prior online registration required! 09:15-09:30 Introduction and Overview of GEP NETs Martyn Caplin, GBR 09:30-09:50 Carcinoid Syndrome Management and New Advances Gregory Kaltsas, GRE 09:50-10:10 Somatostatin Analogues Anti-Tumor Effect: More Understanding in the Last Year Marianne Ellen Pavel, GER 10:10-10:30 Ectopic Hormones and Paraneoplastic Syndromes Associated with NETs Wouter de Herder, NED 10:40-11:00 Case Study David Gross, ISR 11:30-11:50 Management for Pancreatic NET Towards a New Algorithm Juan Valle, GBR 11:50-12:10 Locoregional Therapy for Liver Disease: Transarterial Embolization - Yttrium Radioembolization, Radiofrequency Ablation Ricarda Seidensticker, GER 12:20-12:40 Case Presentation Christos Toumpanakis, GBR 13:40-14:00 Where are we with Personalised Management? Tim Meyer, GBR 14:00-14:20 Quality of Life Measurement in NET Patients John Ramage, GBR 14:20-14:40 How Best to Manage Non-Secretory Causes of Diarrhea Ulrich-Frank Pape, GER 15:10-15:30 Appendix Neuroendocrine Tumors Ulrich Peter Knigge, DEN 15:30-15:50 Management of NETs in Unusual Sites: Brain, Heart, Eyes, Ovaries Kjell Öberg, SWE 16:00-16:20 Diagnosis of Pulmonary NETs Pier Luigi Filosso, ITA 16:20-16:40 Management of Pulmonary NETs Eric Baudin, FRA 16:40-17:00 Medullary Thyroid Carcinoma Ashley Grossman, GBR

Scientific Program 5 17:10-17:15 Closing Remarks Martyn Caplin, GBR Welcome Reception Time: Wednesday 17:15-18:15 Room: Foyer in front of 112, First floor

Scientific Program 6 Thursday, 10.03.2016 Meet the Professor Time: Thursday 07:20-08:25 Meeting room 125 Meeting room 123 Meeting room 124 Meeting room 127 Meeting room 128 Advance in Paraganglioma and Phaeochromocytoma Ashley Grossman, GBR Role of Transarterial Embolisation Philippe Ruszniewski, FRA Tricks for Controlling Difficult NET Syndromes Barbro Eriksson, SWE How Do I Choose Chemotherapy? Nicola Fazio, ITA Genomics and Epigenomics in NETs Christina Thirlwell, GBR Welcome and Introduction Time: Thursday 08:15-08:45 08:30-08:45 Welcome and Introduction Martyn Caplin, GBR Session 1: New Understanding in NET Tumorigenesis Time: Thursday 08:45-10:10 Chairs: Aldo Scarpa, ITA; Kjell Öberg, SWE 08:45-09:10 Overview - Profiling in GEP NET Aurel Perren, SUI 09:10-09:35 Hallmarks on Neuroendocrine Tumor Development Christopher Heaphy, USA 09:35-10:00 Metabolism and Cancer Dimitrios Anastasiou, GBR 10:00-10:10 Discussion Life Achievement Award 2016 Time: Thursday 10:10-10:30 Chair: Martyn Caplin, GBR 10:10-10:15 Dedication Emanuel Christ, SUI 10:15-10:30 Recipient and Keynote Presentation: Peptide Receptors as Targets in Neuroendocrine Tumors Jean Claude Reubi, SUI

Scientific Program 7 Presentation ENETS Grant Winners 2015 Time: Thursday 10:30-10:45 Chair: Martyn Caplin, GBR 10:30-10:35 CoE Excellence Academy Fellowship Henning Jann, GER 10:35-10:40 CoE Young Investigator Grant Jerome Cros, FRA 10:40-10:45 ENETS Translational Medicine Fellowship Su-Chen Li, SWE Coffee Break and Poster Viewing Time: Thursday 10:45-11:20 Room: Exhibition area Poster reviewing will take place in the poster exhibition area on the ground floor.... Parallel Sessions Session 2A: Predictive Biomarkers for NETS Time: Thursday 11:20-12:30 Room: Meeting room 111 Chairs: Anne Couvelard, FRA; Tim Meyer, GBR 11:20-11:35 Tissue Markers Jean-Yves Scoazec, FRA 11:35-11:50 Circulating RNA Mark Kidd, USA 11:50-12:05 Circulating DNA Christina Thirlwell, GBR 12:05-12:15 Discussion 12:15-12:30 Presidential Abstract: Detection of SSTR2 and 5 Expression on Circulating Tumour Cells in Neuroendocrine Tumours Alexa Childs, GBR Session 2B: Pancreas Session with Treatment Time: Thursday 11:20-12:30 Chairs: Frederico Costa, BRA; Ivan Borbath, BEL 11:20-11:35 Molecular Imaging for Pancreatic Neuroendocrine Tumors Damian Wild, SUI 11:35-11:50 Laparoscopic Versus Open Surgery for Pancreatic NETs Elisabeth Nieveen van Dijkum, NED 11:50-12:05 Update on Molecular Targeted Agents Versus Chemotherapy for P-NET Rocio Garcia-Carbonero, ESP 12:05-12:15 Discussion 12:15-12:30 Presidential Abstract: Netazepide, A Gastrin/CCK2 Receptor Antagonist, Can Eradicate Gastric Neuroendocrine Tumours in Patients with Autoimmune Chronic Atrophic Gastritis Malcolm Boyce, GBR Satellite Symposium I, Industry - Sponsored - Symposium Time: Thursday 12:30-14:00 Room: Meeting room 112

Scientific Program 8 For Symposium participants lunch boxes will be available in the meeting room. Lunch Time: Thursday 12:30-14:00 Room: Exhibition area... Parallel Sessions Session 3A: Basic Science Abstract Session Time: Thursday 14:00-15:15 Room: Meeting room 111 Chairs: Anne Couvelard, FRA; Staffan Welin, SWE 14:00-14:15 A Novel Hereditary Pancreatic Neuroendocrine Tumor Syndrome Associated with Biallelic Inactivation of the Glucagon Receptor Laura Tang, USA 14:15-14:30 Midkine is a New Novel Serum Biomarker in Small Intestinal Neuroendocrine Tumors (SI- NETs) Kosmas Daskalakis, SWE 14:30-14:45 Splicing Dysregulation Impacts on Neuroendocrine Tumors: Evidence from Altered Spliceosoma Components and Somatostatin and Ghrelin Systems Justo P. Castaño, ESP 14:45-15:00 Epigenetic Remodeling upon DAXX and ATRX Loss in Pancreatic Neuroendocrine Tumors (pnets) Ilaria Marinoni, SUI 15:00-15:15 The Role of p27 in Pheochromocytoma Development Andrea Richter, GER Session 3B: Clinical Abstract Session Time: Thursday 14:00-15:15 Chairs: Nicholas Simon Reed, GBR; Philippe Ruszniewski, FRA 14:00-14:15 Significance of Preoperative FDG-PET/CT Scan in Patients with Pulmonary Carcinoid Tumours Georgios Papaxoinis, GBR 14:15-14:30 Evaluation of the Somatostatin, CXCR4 Chemokine and Endothelin A Receptor Expression in a Large Series of Paragangliomas Daniel Kaemmerer, GER 14:30-14:45 Extra-pulmonary Neuroendocrine Carcinomas: A National Population Based Study Jan Maarten Van Der Zwan, NED 14:45-15:00 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs Mark Kidd, USA 15:00-15:15 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years Richard P. Baum, GER Coffee Break and Poster Viewing Time: Thursday 15:15-15:40 Room: Exhibition area Poster reviewing will take place in the poster exhibition area on the ground floor. Session 4: ENETS / EANM Joint Symposium: PRRT - Peptide Receptor Radionuclide Therapy Time: Thursday 15:40-17:15 Chairs: Bertram Wiedenmann, GER; Lisa Bodei, ITA

Scientific Program 9 15:40-16:20 PRRT Versus Medical Therapy for Intestinal NET Debate: 15:40-15:50 PRRT Richard P. Baum, GER 15:50-16:00 Medical Treatments Kjell Öberg, SWE 16:00-16:05 Rebuttal Comments Kjell Öberg, SWE Richard P. Baum, GER 16:05-16:20 Audience Discussion 16:20-16:35 Are We Ready for Combination Therapy with PRRT and Chemo or Biotherapy? Rodney Hicks, AUS 16:35-16:50 Novel Isotopes Helmut Maecke, GER 16:50-17:00 Discussion 17:00-17:15 Presidential Abstract: Somatostatin Receptor PET/CT w. Radiolabeled Antagonist is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of Phase 1/2 Study Comp. 68Ga-OPS202 w. 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients Guillaume Nicolas, SUI ENETS General Assembly Time: Thursday 17:15-18:15 Room: Meeting room 111 Every ENETS member is welcome to attend the Society s Annual General Assembly meeting. Only ENETS members are allowed entry to the Annual General Assembly meeting and only those members who have paid all their membership fees up to 2016 latest until 13:00 on 10 March 2016 are entitled to vote on any agenda items. Satellite Symposium II, Industry - Sponsored - Symposium Time: Thursday 18:10-19:45 Room: Meeting room 112 Meet the Professor Time: Thursday 19:00-20:00 Meeting room 123 Meeting room 127 Meeting room 128 ProductionTestMTP-1-R123 ProductionTest1-MTP-R127 ProductionTest1-MTP-R128

Scientific Program 10 Friday, 11.03.2016 Meeting room 123 Meeting room 124 Meeting room 125 Meeting room 127 Meeting room 128 Role of Transarterial Embolisation Philippe Ruszniewski, FRA Tricks for Controlling Difficult NET Syndromes Barbro Eriksson, SWE Advance in Paraganglioma and Phaeochromocytoma Ashley Grossman, GBR How Do I Choose Chemotherapy? Nicola Fazio, ITA Genomics and Epigenomics in NETs Christina Thirlwell, GBR Session 5: Surgical Debate - Transplant Versus Liver Resection Time: Friday 08:30-09:50 Chairs: Göran Åkerström, SWE; Massimo Falconi, ITA 08:30-09:10 Management of Liver Metastases Debate: 08:30-08:45 Liver Transplantation in NET (Pro) Vincenzo Mazzaferro, ITA 08:45-09:00 Liver Transplantation in NET (Con) Andreas Pascher, GER 09:00-09:10 Discussion 09:10-09:50 Intestinal Surgery in Patients with Unresectable Liver Metastases Debate: 09:10-09:25 Resection of Primary Tumor (Pro) Graeme Poston, GBR 09:25-09:40 No Resection of Primary Tumor (Con) Reza Kianmanesh, FRA 09:40-09:50 Discussion Coffee Break and Poster Viewing Time: Friday 09:50-10:20 Room: Exhibition area Poster reviewing will take place in the poster exhibition area on the ground floor.... Parallel Sessions Session 6A: Treatment of NET G3 OR NEC Time: Friday 10:20-11:20 Chairs: Anja Rinke, GER; Ramon Salazar, ESP 10:20-10:35 Histopathology NET G3 Versus NEC G3 Laura Tang, USA 10:35-10:50 Medical Management of GEP NET/C G3 Halfdan Sorbye, NOR Session 6B: Neuroendocrine Tumor Models Time: Friday 10:20-11:20 Room: Meeting room 111 Chairs: Christian Fischer, GER; Simona Glasberg, ISR 10:20-10:35 Slice Culture Anne Couvelard, FRA 10:35-10:50 Primary Cell Culture and Classical Cell Lines Maria Chiara Zatelli, ITA

Scientific Program 11 10:50-11:05 Management of Atypical Pulmonary NET is Different to SCLC? Eric Baudin, FRA 11:05-11:20 Presidential Abstract: Interim Results on the Influence of Lanreotide on Uptake of [68Ga]- DOTATATE in Patients with Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide before [68Ga]- DOTATATE PET/CT Else Aalbersberg, NED 10:50-11:05 Zebrafish Holger Gerhard, GER 11:05-11:20 Mouse Models (MEN1 and RIP-Tag) Rajesh Thakker, GBR Session 7Ai: Molecular Targeted Agents and Angiogenesis Time: Friday 11:20-12:20 Chairs: Diego Ferone, ITA; Jonathan Strosberg, USA 11:20-11:40 Angiogenesis Inhibitors: Where Are We Now? Jaume Capdevila, ESP 11:40-12:00 PI3 Kinase Pathways and mtor Inhibitors: Where Are We Now? Marianne Ellen Pavel, GER 12:00-12:20 What Is The Future for New Molecular Targeted Agents? Eric Raymond, FRA Session 7B: ENETS NET Nurse Symposium Time: Friday 11:20-12:35 Room: Meeting room 111 Chairs: Jenny Falkerby, SWE; Philippa Davies, GBR 11:20-11:25 Introduction Jenny Falkerby, SWE 11:25-11:35 Update, What s New in the Field? Joakim Crona, SWE 11:35-11:45 Is 5HIAA Measurement in Blood Useful in Neuroendocrine Patients? Camilla Schalin-Jantti, FIN 11:45-11:55 Temzolomide/Capecitabine in Neuroendocrine Tumors: A Single Center Review Lynne McCallum, GBR 11:55-12:00 Question and Answer 12:00-12:10 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors Lisette Saveur, NED 12:10-12:20 NET Patient Cancer Experience Survey Catherine Bouvier, GBR 12:20-12:30 Question and Answer 12:30-12:35 Summary and Close Philippa Davies, GBR Session 7Aii: ENETS Surgical Trials Time: Friday 12:20-12:35

Scientific Program 12 Chair: Dermot O'Toole, IRL 12:20-12:30 Intestine: Resection of Primary Intestinal Tumour Versus Conservative Care in Patients with Unresectable Liver Metastases Reza Kianmanesh, FRA 12:25-12:35 Pancreas: Follow-up Protocol of Sub-2cm Pancreatic NETs Massimo Falconi, ITA ENETS Awards and Grants Ceremony 2016 Time: Friday 12:35-12:45 Chair: Martyn Caplin, GBR Satellite Symposium III, Industry - Sponsored - Symposium Time: Friday 12:45-14:15 Room: Meeting room 112 For Symposium participants lunch boxes will be available in the meeting room. Lunch Time: Friday 12:45-14:15 Room: Exhibition area Session 8: What s New in the Field? Time: Friday 14:15-15:35 Chairs: Diane Reidy Lagunes, USA; Eva Tiensuu Janson, SWE 14:15-14:22 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results Jonathan Strosberg, USA 14:22-14:29 Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period Dieter Hörsch, GER 14:29-14:36 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pnet): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover Eric Raymond, FRA 14:36-14:43 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis Simron Singh, CAN 14:43-14:45 Discussion 14:45-15:05 Overview of Best Clinical and Basic Science Abstracts Robert Jensen, USA 15:05-15:20 What s New in NET Understanding Guido Rindi, ITA

Scientific Program 13 15:20-15:35 Overview of Ongoing and Planned Clinical Trials Ulrich-Frank Pape, GER Closing Comment Time: Friday 15:35-15:45 15:35-15:45 Closing Comment Massimo Falconi, ITA

Contact info 14 ENETS Conference Contacts ENETS - European Neuroendocrine Tumor Society c/o Charité - Universitätsmedizin Berlin Campus Virchow-Klinikum Department of Internal Medicine Division of Hepatology and Gastroenterology Augustenburger Platz 1 13353 Berlin, Germany Tel: ++49(0)30-450 553 096 Fax:++49(0)30-450 553 942 Email: enets.office@charite.de Web: www.enets.org/annual_enets_conference Web: www.enets.org Venue address: Centro de Convenciones Internacional de Barcelona (CCIB) GL events CCIB, SL Willy Brandt Square 11-14 08019 Barcelona, Spain